Child and adolescent immunizations: Selected review of recent US recommendations and literature

Current Opinion in Pediatrics

Volumn 26, Issue 3, 2014, Pages 383-395

  Kao, Carol M ^a   Schneyer, Rebecca J ^a   Bocchini, Joseph A ^b  

^a North Shore Long Island Jewish Health System ^*  (United States)

^b Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

Immunization; vaccine; vaccine effectiveness; vaccine safety

Indexed keywords

ACELLULAR VACCINE; DIPHTHERIA VACCINE; INFLUENZA VACCINE; MENINGOCOCCUS VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; TETANUS TOXOID; WART VIRUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE;

COST EFFECTIVENESS ANALYSIS; DIPHTHERIA; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE PERSONNEL; HUMAN; IMMUNOGENICITY; INFLUENZA; PARENT; PATIENT SELECTION; PERTUSSIS; PNEUMOCOCCAL INFECTION; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; REVIEW; TETANUS; UNITED STATES; VACCINATION; WART VIRUS; ADOLESCENT; CHILD; EPIDEMIOLOGY; IMMUNIZATION; PATIENT ATTITUDE; PATIENT EDUCATION; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; HUMANS; IMMUNIZATION; IMMUNIZATION SCHEDULE; INFLUENZA VACCINES; MENINGOCOCCAL VACCINES; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT EDUCATION AS TOPIC; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 84900386897     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0000000000000093     Document Type: Review

References (64)

1. Centers for Disease Control and Prevention (CDC). Influenza activity-United States, 2012-13 season and composition of the 2013-14 influenza vaccine. MMWR Morb Mortal Wkly Rep 2013; 62:473-479
2. Centers for Disease Control and Prevention (CDC). Flu view: 2013-2014 influenza season week 6 ending February 8, 2014. http://www.cdc.gov/flu/weekly. [Accessed February 2013]
3. Centers for Disease Control and Prevention (CDC). Prevention and control of seasonal infl uenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices-United States, 2013-2014. MMWR Recomm Rep 2013; 62 (RR-07):1-43
4. Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children. Pediatrics 2013; 132:e1089-e1104
5. Domachowske JB, Pankow-Culot H, Bautista M, et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis 2013; 207:1878-1887
6. Langley JM, Carmona Martinez A, Chatterjee A, et al. Immunogenicity a nd safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis 2013; 208: 544-553
7. Block SL, Falloon J, Hirschfield JA, et al. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis J 2012; 31:745-751
8. Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012; 30:1993-1998. A key article that estimates the potential impact of quadrivalent influenza vaccines on influenza-related health outcomes
9. Lee BY, Bartsch SM, Willig AM. The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine 2012; 30:7443-7446
10. Greenhawt MJ, Sp ergel JM, Rank MA, et al. Safe administration of the seasonal trivalent influenza vaccine to children with severe egg allergy. Ann Allergy Asthma Immunol 2012; 109:426-430
11. Des Roches A, Paradis L, Gagnon R, et al., PCIRN (Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network). Egg-allergic patients can be safely vaccinated against influenza. J Allergy Clin Immunol 2012; 130:1213-1216
12. Vesikari T, Block SL, Guerra F, et al. Reactogenicity of a mammalian cellculture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age. Pediatr Infect Dis J 2012; 31:494-500
13. Centers for Disease Control and Prevention (CDC). Flu vaccination coverage, United States, 2012-13 influenza season. Septembe r 2013. http://www. cdc.gov/flu/fluvaxview/coverage-1213estimates.htm. [Accessed February 2013]
14. Lu PJ, Santibanez TA, Williams WW, et al., Immunization Services Division, National Center for Immunization and Respiratory Diseases. Surveillance of influenza vaccination coverage-United States, 2007-08 through 2011-12 influenza seasons. MMWR Surveill Summ 2013; 62 (Suppl. 4):1-29
15. Lin CJ, Nowalk MP, Toback SL, Ambrose CS. Factors associated with in-office influenza vaccination by U.S. pediatric providers. BMC Pediatr 2013; 13:180
16. Bernstein HH, Starke JR, American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement-recommendation for mandatory influenza immunization of all healthcare personnel. Pediatrics 2010; 126: 809-815
17. Centers for Disease Control and Prevention (CDC). Influenza vaccination coverage among health-care personnel-United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep 2013; 62:781-786
18. Rakita RM, Hagar BA, Crome P, Lammert JK. Mandatory influenza vaccination of healthcare workers: a 5-year study. Infect Control Hosp Epidemiol 2010; 31:881-888
19. Quan K Tehrani DM Dickey L et al. Voluntary to mandatory: evolution of strategies and attitudes toward influenza vaccination of healthcare personnel. Infect Control Hosp Epidemiol 2012 33 63-70
20. Miller BL, Ahmed F, Lindley MC, Wortley PM. Increases in vaccination coverage of healthcare personnel following institutional requirements for influenza vaccination: a national survey of U.S. hospitals. Vaccine 2011; 29:9398-9403
21. Centers for Disease Control and Prevention (CDC). Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale. MMWR Morb Mortal Wkly Rep 2013; 62:52-54
22. Cohn AC, MacNeil JR, Clark TA, et al., Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP ). MMWR Recomm Rep 2013; 62 (RR-2):1-28
23. Marshall GS, Blatter M, Marchant C, et al. Antibody persistence for up to 5 years after a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (Hib-MenCY-TT) given at 12-15 months of age. Pediatr Infect Dis J 2013; 32:662-668
24. Food and Drug Administration (FDA). August 1, 2013 approva l letter-Menveo. September 2013. http://www.fda.gov/BiologicsBloodVaccines/ Vaccines/ApprovedProducts/ucm363785.htm. [Accessed December 2013]
25. Centers for Disease Control and Prevention (CDC). Recommended imm unization schedule for persons aged 0 through 18 years-United States, 2014. January 2014. http://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent. html. [Accessed February 2013]
26. Nolan TM, Nissen MD, Naz A, et al. Immunogenicity and safety of a CRMconjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age. Hum Vaccin Immunother 2013; 10:280-289
27. Vesikari T, Esposito S, Prymula R, et al., EU Meningococcal B Infant Vaccine Study group. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitan tly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013; 381:825-835
28. Snape MD, Saroey P, John TM, et al. Persistence of bactericidal antibodies following ear ly infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose. CMAJ 2013; 185:E715-E724
29. Centers for Disease Control and Prevention (CDC). Serogroup B meningococcal vaccine. December 2013. http://www.cdc.gov/meningitis/bacterial. html. [Accessed December 2013]
30. Centers for Disease Contr ol and Prevention (CDC). National and state vaccination coverage among adolescents aged 13-17 years-United States, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:685-693
31. Coyne-Beasley T, Reiter PL, L iberty AC, et al. Awareness is not enough: the need to increase meningococcal vaccine uptake. Clin Pediatr (Phila) 2013; 52:441-450
32. Bechini A, Tiscione E, Boccalini S, Levi M. Acel lular pertussis vaccine use in risk groups (adolescents, pregnant women, newborn and healthcare workers): a review of evidence and recommendations. Vaccine 2012; 30:5179-5180
33. Tartof SY, Lewis M, Keny on C, et al. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics 2013; 131:e1047-e1052
34. Wiley KE, Zuo Y, Macartney KK, McIntyre PB. Sources of pertussis infection in young infants: a review of key evidence informing targeting of the cocoon strategy. Vaccine 2013; 31:618-625
35. Centers for Disease Control and Prevention (CDC). Updated Recommendations for Use of Tetanus Toxoid, R educed Diphtheria Toxoid and Acellular Pertussis Vaccine (Tdap) in Pregnant Women-Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2013; 62:131-135
36. Klein NP, Bartlett J, Rowhani-Rahbar A, et al. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 2012; 367: 1012-1019
37. Klein NP, Bartlett J, Fireman B, et al. Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics 2013; 131: e1716-e1722
38. Talbot EA, Brown KH, Kirkland KB, et al. The safety of immu nizing with tetanus-diphtheria-acellular pertussis less than 2 years following previous tetanus vaccination: Experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. Vaccine 2010; 28:8001-8007
39. Zheteyeva YA, Moro PL, Tepper NK, et al. Adverse event report after tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines in pregnant women. Am J Obstet Gynecol 2012; 207:59.e1-59.e7
40. Shakib JH, Korgenski K, Sheng X, et al. Tetanus, diptheria, acellular pertussis vaccine during pregnancy: pregnancy and infant health outcomes. J Pediatr 2013; 163:1322-1326; 1326. e1-1326.e4
41. Gall SA Myers J Pichichero M. Maternal immunization with tetanus-diphtheriapertussis vaccine: effect on maternal and neonatal serum antibody levels. Am J Obstet Gynecol 2011 204:334.e1-334.e5
42. Healy CM, Rench MA, Baker CJ. Importance of timing of maternal combined tetanus, diphtheria and pertussis immunization and protection of young infants. Clin Infect Dis 2013; 56:539-544
43. Hardy-Fairbanks AJ, Pan SJ, Decker MD, et al. Immune response in infants whose mothers received Tdap vaccine during pregnancy. Pediatr Infect Dis J 2013; 32:1257-1260
44. Terranella A, Asay GR, Messionnier ML, et al. Pregnancy dose Tdap and postpartum cocooning to prevent infant pertussis: a decision analysis. Pediatrics 2013; 131:e1748-e1756
45. Nuorti JP, Whitney CG, Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children-use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine-reco mmendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59 (RR-11):1-18
46. Olarte L, Ampofo K, Stockmann C, et al. Invasive pneumococcal disease in infants younger than 90 days before and after introduction of PCV7. Pediatrics 2013; 132:e17-e24
47. Kaplan SL, Barson WJ, Lin PL, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013; 32:203-207
48. Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in young c hildren before licensure of 13-valent pneumococcal conjugate vaccine-United States, 2007. MMWR Morb Mortal Wkly Rep 2010; 59:253-288
49. Centers for Disease Control and Prevention (CDC). Use of 13-val ent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2013; 62:521-524
50. Marom T, Tan A, Wilkinson GS, et al. Trends in otitis media-related healthcare use in the United States, 2001-2011. JAMA Pediatr 2014; 168:68-75
51. Walter EB, Clements DA. Pneumococcal conjugate vaccine: are 3 doses equal to 4 doses Pediatrics 2013; 132:e498-e499
52. Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination coverage among children aged 19-35 months-United States, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:733-740
53. Stoecker C, Hampton LM, Link-Gelles R, et al. Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine. Pediatrics 2013; 132:e324-e332
54. Stoecker C, Hampton LM, Moore MR. 7-Valent pneumococcal conjugate vaccine and otitis media: effectiveness of a 2-dose versus 3-dose primary series. Vaccine 2012; 30:6256-6262
55. Pelton SI, We ycker D, Klein JO, et al. 7-Valent pneumococcal conjugate vaccine and lower respiratory tract infections: effectiveness of a 2-dose versus 3-dose primary series. Vaccine 2010; 28:1575-1582
56. Sch önberger K, Kirchgässner K, Riedel C, von Kries R. Effectiveness of 2+ 1 PCV7 vaccination schedules in children under 2 years: a meta-analysis of impact studies. Vaccine 2013; 31:5948-5952
57. Deceuninck G, De Wals P, Boulianne N, De Serres G. Effectiveness of pneumococcal conjugate vaccine using a 211 infant schedule in Quebec, Canada. Pediatr Infect Dis J 2010; 29:546-549
58. Scott P, Rutjes AWS, Bermetz L, et al. Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: systematic review and meta-analysis. Vaccine 2011; 29:9711-9721
59. Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013-United States. MMWR Morb Mortal Wkly Rep 2 013; 62:591-595
60. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013; 208:385-393
61. Flagg EW, Schwartz R, Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination. Am J Public Health 2013; 103:1428-1435
62. Darden PM Thompson DM Roberts JR et al. Reasons for not vaccinating adolescents: National Immunization Survey of Teens, 2008-2010. Pediatrics 2013 131 645-651
63. Mullins TL, Griffioen AM, Glynn S, et al. Human papillomavirus vaccine communication: per spectives of 11-12 year-old girls, mothers, and clinicians. Vaccine 2013; 31:4894-4901
64. Reiter PL, Gilkey MB, Brewer NT. HPV vaccination among adolescent males: results from the National Immunization Survey-Teen. Vaccine 2013; 31: 2816-2821.